Pharmacology and potential mechanisms of action of rizatriptan.
Hargreaves
R J
RJ
Merck Sharp and Dohme, Neuroscience Research Centre, Harlow, Essex, UK. richard_hargreaves@merck.com
D001921:Brain / Q000098:blood supply; D006801:Humans; D008881:Migraine Disorders / Q000503:physiopathology*; D009131:Muscle, Smooth, Vascular / Q000294:innervation; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D014230:Triazoles / Q000494:pharmacology*; D014276:Trigeminal Nerve / Q000187:drug effects / Q000503:physiopathology; D014363:Tryptamines
C470302:HTR1B protein, human; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan